Oncternal Therapeutics (ONCT) 10-K 12 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 10, 2014	Jun. 28, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'GTX INC /DE/	'	'
Entity Central Index Key	'0001260990	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$181,397,363
Entity Common Stock, Shares Outstanding	'	75,161,437	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$14,529	$48,044
Short-term investments	200	8,045
Prepaid expenses and other current assets	442	726
Total current assets	15,171	56,815
Property and equipment, net	112	507
Intangible and other assets, net	322	452
Total assets	15,605	57,774
Current liabilities:	'	'
Accounts payable	808	1,707
Accrued expenses and other current liabilities	3,759	7,788
Total current liabilities	4,567	9,495
Other long-term liabilities	354	578
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Common stock, $0.001 par value: 120,000,000 shares authorized at December 31, 2013 and December 31, 2012; 63,185,389 and 62,818,424 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	63	63
Additional paid-in capital	465,981	460,887
Accumulated deficit	-455,360	-413,249
Total stockholders' equity	10,684	47,701
Total liabilities and stockholders' equity	$15,605	$57,774

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
BALANCE SHEETS	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	63,185,389	62,818,424
Common stock, shares outstanding	63,185,389	62,818,424

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Collaboration revenue	$0	$0	$8,066
Expenses:	'	'	'
Research and development expenses	32,318	38,887	31,938
General and administrative expenses	11,281	10,845	12,027
Total expenses	43,599	49,732	43,965
Loss from operations	-43,599	-49,732	-35,899
Other income (expense), net	1,488	-19	398
Loss from operations before income taxes	-42,111	-49,751	-35,501
Income tax benefit	'	8,821	886
Net loss from continuing operations	-42,111	-40,930	-34,615
Income from discontinued operations before income taxes	'	22,676	2,207
Income tax expense	'	-8,821	-886
Net income from discontinued operations	'	13,855	1,321
Net loss	($42,111)	($27,075)	($33,294)
Net (loss) income per share - basic and diluted:	'	'	'
Net loss from continuing operations (in dollars per share)	($0.67)	($0.65)	($0.60)
Net income from discontinued operations (in dollars per share)	'	$0.22	$0.02
Net loss per share (in dollars per share)	($0.67)	($0.43)	($0.58)
Weighted average shares outstanding:	'	'	'
Basic and diluted (in shares)	63,057,142	62,809,219	57,359,466

STATEMENTS_OF_STOCKHOLDERS_EQU

STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2010	$51,727	$52	$404,555	($352,880)
Balance (in shares) at Dec. 31, 2010	'	51,719,187	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Issuance of common stock, net of offering costs	48,982	11	48,971	'
Issuance of common stock, net of offering costs (in shares)	'	11,023,000	'	'
Issuance of common stock under deferred compensation arrangements (in shares)	'	35,036	'	'
Exercise of employee stock options	55	'	55	'
Exercise of employee stock options (in shares)	13,000	13,000	'	'
Directors' deferred compensation	178	'	178	'
Share-based compensation	4,226	'	4,226	'
Net loss	-33,294	'	'	-33,294
Balance at Dec. 31, 2011	71,874	63	457,985	-386,174
Balance (in shares) at Dec. 31, 2011	'	62,790,223	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Exercise of employee stock options	85	'	85	'
Exercise of employee stock options (in shares)	28,201	28,201	'	'
Directors' deferred compensation	169	'	169	'
Share-based compensation	2,648	'	2,648	'
Net loss	-27,075	'	'	-27,075
Balance at Dec. 31, 2012	47,701	63	460,887	-413,249
Balance (in shares) at Dec. 31, 2012	62,818,424	62,818,424	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Issuance of common stock under deferred compensation arrangements (in shares)	'	45,667	'	'
Exercise of employee stock options	1,226	'	1,226	'
Exercise of employee stock options (in shares)	321,298	321,298	'	'
Directors' deferred compensation	135	'	135	'
Share-based compensation	3,733	'	3,733	'
Net loss	-42,111	'	'	-42,111
Balance at Dec. 31, 2013	$10,684	$63	$465,981	($455,360)
Balance (in shares) at Dec. 31, 2013	63,185,389	63,185,389	'	'

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net loss	($42,111)	($27,075)	($33,294)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Gain on sale of FARESTON	'	-18,831	'
Share-based compensation	3,733	2,648	4,226
Directors' deferred compensation	135	169	178
Depreciation and amortization	384	750	1,040
Gain on sale of property and equipment	-1,366	'	'
Deferred revenue amortization	'	'	-8,066
Impairment of intangible assets	'	'	1,598
Changes in assets and liabilities:	'	'	'
Prepaid expenses and other assets	399	1,857	-849
Accounts payable	-899	488	371
Accrued expenses and other liabilities	-4,246	2,885	1,707
Net cash used in operating activities	-43,971	-37,109	-33,089
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	-32	-142	-54
Proceeds from the sale of property and equipment	1,424	'	'
Purchase of short-term investments, held to maturity	-1,425	-11,980	-15,145
Proceeds from maturities of short-term investments, held to maturity	9,270	14,630	4,900
Proceeds from the sale of FARESTON, net of cash expenses	'	18,897	'
Net cash provided by (used in) investing activities	9,237	21,405	-10,299
Cash flows from financing activities:	'	'	'
Proceeds from issuance of common stock	'	'	48,982
Proceeds from exercise of employee stock options	1,226	85	55
Payments on capital lease and financed equipment obligations	-7	-82	-85
Net cash provided by financing activities	1,219	3	48,952
Net (decrease) increase in cash and cash equivalents	-33,515	-15,701	5,564
Cash and cash equivalents, beginning of period	48,044	63,745	58,181
Cash and cash equivalents, end of period	$14,529	$48,044	$63,745

Business

Business	12 Months Ended
	Dec. 31, 2013
Business	'
Business	'
	1.             Business
	GTx, Inc. (“GTx” or the “Company”), a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for prostate and breast cancer, cancer supportive care, including prevention and treatment of cancer-related muscle wasting, and other serious medical conditions.
	The Company is developing selective androgen receptor modulators (“SARMs”), including its lead product candidate, enobosarm (GTx-024).  SARMs are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss), as well as the potential to be used as a novel hormonal therapy for the treatment of metastatic breast cancer.  The Company announced in August 2013 that its two Phase 3 clinical trials evaluating enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer (“NSCLC”) failed to meet the primary statistical criterion for the co-primary endpoints of lean body mass and physical function that were assessed statistically using responder analyses as pre-specified for the United States Food and Drug Administration (“FDA”).  The Company met with representatives from two member countries to the European Medicines Agency (“EMA”) in January of 2014 to review and discuss the results of the POWER trials to determine an appropriate path forward for submitting a marketing authorization application (“MAA”) in the European Union for enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced NSCLC. Based on input from the two member countries, the Company believes data from the POWER 1 trial, as well as supporting data from the POWER 2 trial, are sufficient to support the submission of a MAA to the EMA seeking marketing authorization for enobosarm 3 mg in the more narrow indication of the prevention and treatment of muscle wasting in patients with advanced NSCLC treated with platinum plus taxane chemotherapy.  The Company plans to initiate seven Phase 1 clinical studies that are typically required for registration purposes and develop a pediatric investigational plan, or PIP, necessary for submission of the MAA.  The Company currently expects to submit the MAA to the EMA for enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced NSCLC treated with platinum plus taxane chemotherapy by the first quarter of 2015, after completion of the Phase 1 studies and acceptance of the PIP by the EMA’s Pediatric Committee.  In the Company’s meeting with the FDA in February 2014 to review and discuss the results of the POWER clinical trials, the Company learned that since data from the two POWER trials failed to meet the primary statistical criterion pre-specified for the co-primary endpoints of lean body mass and physical function, the FDA was not willing to accept a new drug application (“NDA”) for enobosarm 3 mg. However, based on input from the FDA meeting, the Company believes there is a regulatory path forward for enobosarm 3 mg in the United States, and the Company plans to meet again with the FDA to discuss a potential Phase 3 clinical program for an indication of muscle wasting or cachexia in patients with NSCLC.
	The Company is conducting a Phase 2 open label study evaluating enobosarm 9 mg for the treatment of androgen receptor positive and estrogen receptor positive metastatic breast cancer in women who have previously responded to hormonal therapy for the treatment of their metastatic breast cancer.  Additionally, the Company is developing GTx-758 (Capesaris®), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a secondary hormonal treatment for advanced prostate cancer used in combination with androgen deprivation therapy.  The Company is presently conducting a Phase 2 clinical trial evaluating GTx-758 as secondary hormonal therapy in men with metastatic and nonmetastatic castration resistant prostate cancer.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies	'
Significant Accounting Policies	'
	2.              Significant Accounting Policies
	Basis of Presentation
	The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).  Additionally, GTx operates in one business segment.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers highly liquid investments with initial maturities of three months or less to be cash equivalents.
	Short-term Investments
	At December 31, 2013 and 2012, short-term investments consisted of Federal Deposit Insurance Corporation (“FDIC”) insured certificates of deposit with original maturities of greater than three months and less than one year.
	Property and Equipment
	Property and equipment is stated at cost. Amortization of leasehold improvements is recognized over the shorter of the estimated useful life of the leasehold improvement or the lease term.  Depreciation is computed using the straight-line method over the estimated useful lives as follows:
	Laboratory and office equipment	3 to 5 years
	Leasehold improvements	3 to 7 years
	Furniture and fixtures	5 years
	Computer equipment and software	3 years
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments, which include cash, cash equivalents, short-term investments, and accounts payable approximate their fair values.  As the Company has the positive intent and ability to hold the certificates of deposit classified as short-term investments until maturity, these investments have been classified as held to maturity investments and are stated at cost, which approximates fair value.  The Company considers these to be Level 2 investments as the fair values of these investments are determined using third-party pricing sources, which generally utilize observable inputs, such as interest rates and maturities of similar assets.
	Concentration of Risk
	Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term investments.  The Company has established guidelines relating to diversification and maturities of its cash equivalents and short-term investments which are designed to manage risk.  The Company’s cash and cash equivalents consist of bank deposits, certificates of deposit, and money market mutual funds.  Bank deposits may at times be in excess of FDIC insurance limits.  The Company’s short-term investments consist of FDIC insured certificates of deposit with original maturities of greater than three months and less than one year.
	Research and Development Expenses
	Research and development expenses include, but are not limited to, the Company’s expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees.  The Company expenses these costs in the period in which they are incurred. The Company estimates its liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon the Company’s estimate of services received and degree of completion of the services in accordance with the specific third party contract.  As a result of the October 2013 reduction in its workforce, the Company is no longer conducting drug discovery activities and is focusing its research and development activities on the ongoing clinical development of the Company’s current product candidates.  See Note 13, Restructuring, for further discussion.
	Patent Costs
	The Company expenses patent costs, including legal expenses, in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the Company’s statements of operations.
	Income Taxes
	The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Accordingly, at December 31, 2013 and December 31, 2012, net of the valuation allowance, the net deferred tax assets were reduced to zero.  See Note 9, Income Taxes, for further discussion.
	The Company has recognized the tax effect of discontinued operations in the statements of operations in accordance with the intra-period accounting rules.  An offsetting tax benefit was recorded in continuing operations in each year in which tax expense was recognized for discontinued operations.
	Share-Based Compensation
	The Company has stock option and equity incentive plans that provide for the purchase or acquisition of the Company’s common stock by certain of the Company’s employees and non-employee directors.  The Company recognizes compensation expense for its share-based payments based on the fair value of the awards over the period during which an employee or non-employee director is required to provide service in exchange for the award.  See Note 3, Share-Based Compensation, for further discussion.
	Other Income (Expense), Net
	Other income (expense), net consists of foreign currency transaction gains and losses, interest earned on the Company’s cash, cash equivalents and short-term investments, interest expense, and other non-operating income or expense.  Additionally, other income (expense), net for the year ended December 31, 2013 included a gain of $1,366 from the sale of research and development property and equipment sold subsequent to the workforce reduction that occurred in October 2013.  See Note 4, Property and Equipment, Net, and Note 13, Restructuring, for further discussion.
	Basic and Diluted Net Loss Per Share
	Basic and diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of common shares outstanding during the period.  Diluted net loss per share gives effect to the dilutive potential of common stock consisting of stock options and unvested restricted stock units (“RSUs”).
	Weighted average potential shares of common stock of 6,773,394, 5,574,915, and 5,327,752 were excluded from the calculation of diluted net loss per share for the years ended December 31, 2013, 2012 and 2011, respectively, as inclusion of the potential shares would have had an anti-dilutive effect on the net loss per share for the periods.  At December 31, 2013, the Company had outstanding 63,185,389 shares of common stock.
	Comprehensive Loss
	For all periods presented, there were no differences between net loss and comprehensive loss.
	Discontinued Operations
	Effective September 30, 2012, the Company entered into an asset purchase agreement (the “FARESTON® Purchase Agreement”) with Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights and certain assets related to FARESTON®.  The Company has accounted for FARESTON® as a discontinued operation.  As a result, revenue, cost of goods sold, and operating expenses related to FARESTON® were excluded from the respective captions in the statement of operations and were included in discontinued operations for the years ended December 31, 2012 and 2011.  See Note 14, Discontinued Operations, for further discussion.
	FARESTON® Revenue Recognition
	Revenue from product sales of FARESTON®, which is included in income from discontinued operations before income taxes for the years ended December 31, 2012 and 2011, was recognized less deductions for estimated sales discounts and sales returns.  Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured.  The Company accounted for rebates to certain governmental agencies as a reduction of product sales.  The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date.  Although the Company sold its rights and certain assets related to FARESTON® effective September 30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON® made by the Company prior to September 30, 2012.  Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date.  At December 31, 2013 and December 31, 2012, the Company’s accrual for product returns, was $918 and $1,189, respectively.   Of these amounts, $332 and $370 have been included in “Other long-term liabilities” in the balance sheet at December 31, 2013 and December 31, 2012, respectively, and represents the portion of the Company’s product returns accrual estimated to be payable after one year.  See Note 14, Discontinued Operations, for further discussion.
	Collaboration Revenue Recognition
	Collaboration revenue for the year ended December 31, 2011 consisted of non-refundable upfront payments and license fees associated with the Company’s former collaboration and license agreement with Ipsen Biopharm Limited.  Revenues from the prior collaboration and license agreement were recognized based on the performance requirements of the agreement.  The Company analyzed the agreement, which included multiple element arrangements, to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting.  See Note 7, Collaboration and License Agreements, for further discussion.
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets.  An impairment loss is recognized when estimated future cash flows are less than the carrying amount.  The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time.  See Note 8, Intangible Assets, Net for further discussion.
	Subsequent Events
	The Company has evaluated all events or transactions that occurred after December 31, 2013 up through the date the financial statements were issued.  Other than as set forth below, there were no material recognizable or nonrecognizable subsequent events during the period evaluated.
	On March 6, 2014, the Company completed a private placement of units consisting of an aggregate of 11,976,048 shares of common stock and warrants to purchase an aggregate of 10,179,642 shares of our common stock per unit for gross proceeds of $21,272.  The warrants, which have a one year term, have a per share exercise price of $1.67 that is payable only in cash.  Pursuant to the terms of a registration rights agreement dated March 6, 2014 that the Company entered into with the investors, the Company agreed to file a registration statement under the Securities Act registering the resale of all 22,155,690 shares held by or issuable to the investors.  No underwriting discounts or commissions or similar fees were payable in connection with the issuance.

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2013
Share-Based Compensation	'
Share-Based Compensation	'
	3.    Share-Based Compensation
	Share-based payments include stock option grants and, beginning in October 2013, RSUs under the Company’s stock option and equity incentive plans and deferred compensation arrangements for the Company’s non-employee directors.
	The Company has granted and continues to grant to employees and non-employee directors options to purchase common stock under various plans, including the GTx, Inc. 2013 Equity Incentive Plan (the “2013 EIP”) and the GTx, Inc. 2013 Non-Employee Director Equity Incentive Plan (the “2013 NEDEIP”).  On May 2, 2013, the Company’s stockholders approved the 2013 EIP and the 2013 NEDEIP, each of which became effective on that date. The 2013 EIP is the successor to the Company’s 2004 Equity Incentive Plan (the “2004 EIP”), and the 2013 NEDEIP is the successor to the Company’s Amended and Restated 2004 Non-Employee Directors’ Stock Option Plan (the “2004 NEDSOP”).  The total number of shares of the Company’s common stock available for issuance under the 2013 EIP was initially 4,208,157 shares plus up to an additional 6,093,559 shares subject to outstanding awards granted under the 2004 EIP and each of the Genotherapeutics, Inc. Stock Option Plan, the GTx, Inc. 2000 Stock Option Plan, the GTx, Inc. 2001 Stock Option Plan and the GTx, Inc. 2002 Stock Option Plan (collectively, the “Prior Plans”) that, from and after the effective date of the 2013 EIP, expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to vest in those shares or are otherwise returned to the 2013 EIP share reserve pursuant to the terms of the plan. In addition, the shares of the Company’s common stock available for issuance under the 2013 EIP will automatically increase on January 1st of each year, for ten years, commencing on January 1, 2014, in an amount equal to 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, or such lesser (or no) amount as may be approved by the Company’s Board of Directors. The total number of shares of the Company’s common stock available for issuance under the 2013 NEDEIP was initially 404,000 shares plus up to an additional 449,667 shares subject to outstanding awards granted under the 2004 NEDSOP that, from and after the effective date of the 2013 NEDEIP, expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to vest in those shares or are otherwise returned to the 2013 NEDEIP share reserve pursuant to the terms of the plan. In addition, the shares of the Company’s common stock available for issuance under the 2013 NEDEIP will automatically increase on January 1st of each year, for ten years, commencing on January 1, 2014, in an amount equal to the lesser of 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year and 500,000 shares, or such lesser (or no) amount as may be approved by the Company’s Board of Directors. From and after the effective date of 2013 EIP and the 2013 NEDEIP, no further awards will be made under the Prior Plans and the 2004 NEDSOP. Stock options previously granted under the Prior Plans and the 2004 NEDSOP continue to be governed by the terms of the applicable plan.  The 2013 EIP provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, other stock awards, and performance awards that may be settled in cash, stock, or other property.  The 2013 NEDEIP provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, other stock awards, and performance awards that may be settled in cash, stock, or other property.
	Options granted under the 2013 EIP and the 2013 NEDEIP, and prior to May 2, 2013, the Prior Plans and the 2004 NEDSOP, are granted at prices equal to the fair market value of the stock on the dates the options are granted as determined in accordance with the terms of the applicable plan. The options have a term of ten years from the grant date and generally vest over three years from the grant date for director options and over periods of up to five years from the grant date for employee options.  Under the terms of the Company’s stock option and equity incentive plans, employees generally have three months after the employment relationship ends to exercise all vested options except in the case of voluntary retirement, disability or death, where post-termination exercise periods are generally longer.  As described below, however, certain of the Company’s outstanding options were modified to provide an extended post-termination exercise period.  The Company issues new shares of common stock upon the exercise of options.  The Company estimates the fair value of certain stock option awards as of the date of the grant by applying the Black-Scholes-Merton option pricing valuation model. The application of this valuation model involves assumptions that are judgmental and highly sensitive in the determination of compensation expense.
	The fair value of each option is amortized into compensation expense on a straight-line basis between the grant date for the award and each vesting date. The amount of share-based compensation expense recognized is reduced ratably over the vesting period by an estimate of the percentage of options granted that are expected to be forfeited or canceled before becoming fully vested.
	The Company estimates the fair value of RSUs using the closing price of its stock on the grant date.  The fair value of RSUs is amortized on a straight-line basis over the requisite service period of the awards.
	As part of the October 2013 workforce reduction, the Company modified stock options of the terminated employees to accelerate the vesting of certain outstanding non-vested stock options and to extend the post-termination exercise period of their vested stock options.  The terminated employees’ stock options were modified to accelerate the vesting of all outstanding and unvested stock options as if an employee had remained in continuous service as an employee of the Company through January 1, 2014.  Further, the Company extended the post-termination exercise period of each terminated employee’s outstanding and vested options until the earliest to occur of (i) June 1, 2014, (ii) the expiration of the original term of the particular option, and (iii) a change of control of the Company (as defined in the applicable form of award agreement).
	As part of the Company’s efforts to retain the essential employees continuing with the Company following the October 2013 workforce reduction, the Company modified certain stock options held by continuing employees to accelerate the vesting of certain outstanding non-vested stock options and to extend the post-termination exercise period of vested stock options.  For these continuing employees, each of their outstanding stock options was modified to provide that if the employee’s service continues through the earlier to occur of (i) the end of business on May 31, 2014, and (ii) an involuntary termination of employment by the Company (excluding a termination for cause (as defined in the applicable form of retention benefits agreement) or a voluntary resignation) (the “Determination Date”), then, as of the Determination Date: (i) an additional number of shares subject to such option will immediately vest as if the employee’s service had continued through January 1, 2015 and (ii) the period during which the vested portion of such options will generally expire will be extended from 90 days to six months after the employee’s termination of service, subject in each case to the earlier expiration of the original term of the applicable stock option award.
	Additionally, effective October 1, 2013, the Compensation Committee approved a grant of stock options and RSUs under the 2013 EIP to the continuing employees. Both the options granted and the RSUs vest in full on the earlier to occur of (i) June 1, 2014, (ii) an involuntary termination of the award holder’s continuous service by the Company other than for cause (as defined in the applicable form of award agreement) and (iii) a change of control of GTx (as defined in the applicable form of award agreement), except that vesting will not occur in the event of a voluntary resignation or involuntary termination for cause occurring prior to any of these events.
	The following table summarizes share-based compensation expense included within the statements of operations for each of the three years in the period ended December 31, 2013:
		Years Ended December 31,
		2013			2012			2011
	Research and development expenses	$	1,875		$	1,046		$	1,972
	General and administrative expenses	1,993			1,771			2,432
	Total share-based compensation	$	3,868		$	2,817		$	4,404
	Share-based compensation expense recorded in the statement of operations as general and administrative expense for the years ended December 31, 2013, 2012 and 2011 included share-based compensation expense related to deferred compensation arrangements for the Company’s non-employee directors of $135, $169 and $178, respectively.  See Note 10, Directors’ Deferred Compensation Plan, for further discussion of deferred compensation arrangements for the Company’s non-employee directors.
	As a result of the October 2013 modifications of certain stock options held by terminated employees, the Company recognized a net benefit of approximately $370 resulting from the reversal of previously recognized share-based compensation expense that was in excess of the modified fair value of the options.  Of this amount, $81 was included as a benefit to general and administrative expenses and $289 was included as a benefit to research and development expenses for the year ended December 31, 2013.  Additionally, share-based compensation expense for the year ended December 31, 2013 included expense related to the amortization of RSUs which were granted in the fourth quarter of 2013.  The modifications of certain stock options held by the Company’s continuing employees did not have a material impact on share-based compensation expense recognized during the period.
	Share-based compensation expense recorded as research and development expenses for the year ended December 31, 2012 was reduced by the reversal of previously recognized share-based compensation expense for non-vested stock options that were canceled in conjunction with the resignation of an executive officer during the year.
	As part of a June 2011 workforce reduction, the Company modified certain stock options of three terminated non-executive officers to accelerate the vesting of certain outstanding non-vested stock options and to extend the post-termination exercise period of their vested stock options. As a result of these modifications, the Company incurred a one-time share-based compensation charge of $481, which was included in general and administrative expenses for the year ended December 31, 2011. This charge was offset by the reversal of $704 of previously recognized share-based compensation expense for non-vested stock options that were canceled in conjunction with the total workforce reduction. Of this amount, $646 was included in general and administrative expenses and $58 was included in research and development expenses for the year ended December 31, 2011.
	Additionally, share-based compensation expense of $137 included in the table above as general and administrative expenses was reported as discontinued operations in the statement of operations for the year ended December 31, 2011.  There was no share-based compensation expense included in discontinued operations for the years ended December 31, 2013 or 2012.
	For the years ended December 31, 2013, 2012 and 2011, the weighted average grant date fair value per share of options granted was $2.13, $2.14 and $1.75, respectively.  The weighted average for key assumptions used in determining the grant date fair value of options granted in 2013, 2012 and 2011, and a summary of the methodology applied to develop each assumption is as follows:
		Years Ended December 31,
		2013		2012		2011
	Expected price volatility	82.9	%	69.6	%	64.9	%
	Risk-free interest rate	1.27	%	1.22	%	2.54	%
	Weighted average expected life in years	5.9 years		6.5 years		6.5 years
	Dividend yield	0	%	0	%	0	%
	Expected Price Volatility - This is a measure of the amount by which a price has fluctuated or is expected to fluctuate.  The Company based its determination of expected volatility on its historical stock price volatility.  An increase in the expected price volatility will increase compensation expense.
	Risk-Free Interest Rate - This is determined using U.S. Treasury rates where the term is consistent with the expected life of the stock options.  An increase in the risk-free interest rate will increase compensation expense.
	Expected Life - This is the period of time over which the options granted are expected to remain outstanding and is determined by calculating the average of the vesting term and the contractual term of the options.  The Company has utilized this method due to the lack of historical option exercise information related to the Company’s stock option and equity incentive plans.  Options granted have a maximum term of ten years.  An increase in the expected life will increase compensation expense.
	Dividend Yield - The Company has not made any dividend payments nor does it have plans to pay dividends in the foreseeable future.  An increase in the dividend yield will decrease compensation expense.
	The following is a summary of stock option transactions for all of the Company’s stock option and equity incentive plans for the three year period ended December 31, 2013:
		Number of		Weighted
		Shares		Average
				Exercise Price
				Per Share
	Options outstanding at January 1, 2011	4,430,495		10.91
	Options granted	1,395,000		2.82
	Options forfeited or expired	(866,930	)	8.23
	Options exercised	(13,000	)	4.2
	Options outstanding at December 31, 2011	4,945,565		9.12
	Options granted	1,141,250		3.35
	Options forfeited or expired	(675,755	)	8.82
	Options exercised	(28,201	)	3.05
	Options outstanding at December 31, 2012	5,382,859		7.96
	Options granted	2,784,200		3.12
	Options forfeited or expired	(1,400,419	)	5.86
	Options exercised	(321,298	)	3.81
	Options outstanding at December 31, 2013	6,445,342		6.58
	Options vested and expected to vest at December 31, 2013	6,378,284		6.61
	The following table summarizes information about stock options outstanding at December 31, 2013:
	Options Outstanding								Options Exercisable
	Exercise Price	Number		Weighted		Weighted			Number	Weighted
		Outstanding		Average		Average			Exercisable	Average
				Remaining		Exercise Price				Exercise
				Contractual						Price
				Life (years)
	$1.51 - $3.36	2,662,100		7.79		$	2.49		642,501	$	2.96
	$3.44 - $9.71	2,150,947		5.77		4.88			1,023,482	5.58
	$9.80 - $20.40	1,632,295		2.63		15.48			1,515,137	15.43
		6,445,342		5.81		6.58			3,181,120	9.74
	At December 31, 2013, the aggregate intrinsic value of all outstanding options was less than $1 with a weighted average remaining contractual term of 5.81 years.  Of the Company’s outstanding options, 3,181,120 options were exercisable and had a weighted average remaining contractual term of 2.92 years and no aggregate intrinsic value.  Additionally, the Company’s vested and expected to vest options had a weighted average remaining contractual term of 5.78 years and an intrinsic value of less than $1.
	Options to purchase 321,298 shares were exercised during the year ended December 31, 2013.  The total intrinsic value of options exercised during the years ended December 31, 2013, 2012 and 2011 was $688, $36 and $15, respectively.  At December 31, 2013, the total compensation cost related to non-vested options not yet recognized was $4,390, with a weighted average expense recognition period of 1.97 years.  Shares available for future issuance under the Company’s stock option and equity incentive plans were 3,239,443 at December 31, 2013.  On January 1, 2014, shares available for future issuance under the 2013 EIP and 2013 NEDEIP increased by an aggregate of 3,027,416 shares in accordance with the automatic increase provisions of such plans.
The following is a summary of the Company’s RSUs for the year ended December 31, 2013:
	Number of		Weighted
	Shares		Average Grant
			Date Fair Value
			Per Share
Unvested RSUs at January 1, 2013	—		—
RSUs granted	1,325,000		1.87
RSUs vested	—		—
RSUs forfeited	(100,000	)	1.88
Unvested RSUs at December 31, 2013 2013	1,225,000		1.87
At December 31, 2013, the total compensation cost related to non-vested RSUs not yet recognized was $1,443, with a weighted average expense recognition period of five months.

Property_and_Equipment_Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2013
Property and Equipment, Net	'
Property and Equipment, Net	'
	4.              Property and Equipment, Net
	Property and equipment, net consisted of the following:
		December 31,
		2013			2012
	Computer equipment and software	$	2,130		$	4,177
	Furniture and fixtures	1,032			2,706
	Leasehold improvements	355			1,361
	Office and laboratory equipment	261			1,024
		3,778			9,268
	Less: accumulated depreciation	(3,666		)	(8,761		)
		$	112		$	507
	Depreciation and amortization expense for the years ended December 31, 2013, 2012 and 2011 was $369, $730 and $998, respectively.  Of these amounts, $169, $290 and $425, respectively, were included in research and development expenses in the statements of operations.
	Subsequent to the reduction in workforce implemented in October 2013 and determination to cease drug discovery activities, the Company sold its related property and equipment and recognized a gain of $1,366 during the year ended December 31, 2013.  The carrying value associated with the property and equipment that was sold was $58 and related to laboratory equipment.  See Note 13, Restructuring, for further discussion.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities	'
Accrued Expenses and Other Current Liabilities	'
	5.                 Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities consisted of the following:
		December 31,
		2013		2012
	Employee compensation	$	1,354	$	294
	Clinical trials	1,127		5,621
	Product returns	586		819
	Selling, general and administrative	497		737
	Research and development	39		46
	Net deferred income tax liabilities	156		271
		$	3,759	$	7,788

Common_and_Preferred_Stock

Common and Preferred Stock	12 Months Ended
	Dec. 31, 2013
Common and Preferred Stock	'
Common and Preferred Stock	'
	6.              Common and Preferred Stock
	The Company’s certificate of incorporation authorizes the Company to issue 120,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share.
	On November 1, 2010, the Company completed an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $2.80 per share.  Net cash proceeds from the public offering were approximately $37,700 after deducting underwriting discounts and commissions and other offering expenses.  The Company also granted the underwriter a 30-day option to purchase up to an additional 2,142,857 shares of common stock to cover over-allotments, if any.  On November 24, 2010, the underwriter exercised its option and purchased an additional 1,000,000 shares of the Company’s common stock at a price of $2.80 per share.  Net cash proceeds from the exercise of the over-allotment option were approximately $2,600 after deducting underwriting discounts and commissions and other offering expenses.
	On May 6, 2011, the Company filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation with the Secretary of the State of Delaware to increase the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 60,000,000 shares to 120,000,000 shares.  The amendment was approved by the Company’s stockholders at the Company’s 2011 Annual Meeting of Stockholders held on May 5, 2011.
	On June 28, 2011, the Company completed an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.75 per share.  The Company also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.  The underwriters exercised this option and purchased an additional 1,023,000 shares of the Company’s common stock on June 28, 2011 at a price of $4.75 per share.  Net cash proceeds from the public offering were approximately $49,000 after deducting the underwriting discount and offering expenses.

Collaboration_and_License_Agre

Collaboration and License Agreements	12 Months Ended
	Dec. 31, 2013
Collaboration and License Agreements	'
Collaboration and License Agreements	'
	7.              Collaboration and License Agreements
	University of Tennessee Research Foundation License Agreement
	The Company and the University of Tennessee Research Foundation (“UTRF”) are parties to a consolidated, amended and restated license agreement (the “SARM License Agreement”) pursuant to which the Company has been granted exclusive worldwide rights in all existing SARM technologies owned or controlled by UTRF, including all improvements thereto, and exclusive rights to future SARM technology that may be developed by certain scientists at the University of Tennessee or subsequently licensed to UTRF under certain existing inter-institutional agreements with The Ohio State University.  Under the SARM License Agreement, the Company is obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and mid single-digit royalties on sublicense revenues.
	Former Orion Corporation License and Supply Agreement
	In connection with the Company’s sale of its rights and certain assets related to FARESTON® to ProStrakan, the Company and Orion agreed to terminate the Amended and Restated License and Supply Agreement, dated January 1, 2005, as amended, between the Company and Orion (the “Orion Supply Agreement”) as well as certain other agreements between the Company and Orion related to the Orion Supply Agreement (collectively, the “Orion Agreements”). Pursuant to the Orion Supply Agreement, the Company obtained an exclusive license from Orion to develop and commercialize toremifene-based products for all human indications worldwide, except breast cancer outside of the United States, and Orion agreed to manufacture and supply all of the Company’s needs for clinical trial and commercial grade material for toremifene-based products developed and marketed in the United States and abroad, including toremifene globally and FARESTON® in the United States. The termination of the Orion Agreements was effective September 30, 2012.  As consideration for Orion’s agreement to terminate the Orion Agreements and to enter into certain agreements with ProStrakan to effect the FARESTON® sale, the Company paid Orion $1,000 in October 2012.  See Note 14, Discontinued Operations, for further discussion.
	Former Ipsen Collaboration and License Agreement
	In September 2006, the Company entered into a collaboration and license agreement with Ipsen Biopharm Limited (the “Ipsen Collaboration Agreement”) pursuant to which the Company granted Ipsen exclusive rights in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of Independent States (the “European Territory”) to develop and commercialize toremifene in all indications which the Company has licensed from Orion, which include all indications in humans except the treatment and prevention of breast cancer outside of the United States.   In accordance with the terms of the Ipsen Collaboration Agreement, Ipsen paid the Company €23,000 as a license fee and expense reimbursement.  Under the Ipsen Collaboration Agreement, the Company recorded deferred revenue of $29,330 related to the Ipsen upfront license fee and expense reimbursement which was being amortized into revenue on a straight-line basis over the estimated ten year development period for toremifene in the European Territory.
	In March 2011, the Company reacquired full rights to its toremifene program following the termination by the Company and Ipsen of the collaboration and license agreement, as amended.  During the first quarter of 2011, the Company recognized as collaboration revenue all of the remaining $8,066 unamortized revenue.  This amount is included in collaboration revenue in the statement of operations for the year ended December 31, 2011.

Intangible_Assets_Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2013
Intangible Assets, Net	'
Intangible Assets, Net	'
	8.              Intangible Assets, Net
	In accordance with the terms of the former Orion Supply Agreement, the Company paid a license fee to Orion of $4,826.  In accordance with the terms of the SARM License Agreement that the Company entered into with UTRF in July 2007, the Company paid a one-time up-front fee of $290.
	In 2011 after discontinuing the toremifene 80 mg development program, the Company recorded an impairment charge of $1,598.  The impaired intangible asset consisted of capitalized license fees related to the Company’s toremifene 80 mg program paid under the Orion Supply Agreement.  The impairment charge was included in research and development expenses in the statement of operations for the year ended December 31, 2011.
	The Company’s remaining intangible asset, net at December 31, 2013 and 2012 consisted of $166 and $181, respectively, related to the SARM License Agreement.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	9.  Income Taxes
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  The principal components of the Company’s net deferred income tax assets and liabilities consisted of the following:
		December 31,
		2013			2012
	Deferred income tax assets, net:
	Net federal and state operating loss carryforwards	$	127,819		$	112,233
	Research and development credits	11,934			9,799
	Share-based compensation	8,670			8,852
	Depreciation and amortization	170			331
	Other, net	268			328
	Total deferred tax assets, net	148,861			131,543
	Valuation allowance	(148,861		)	(131,543		)
	Net deferred tax assets and liabilities	$	—		$	—
	Realization of deferred income tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.  Accordingly, due to the Company’s history of net operating losses, the net deferred tax assets have been fully offset by a valuation allowance.  The valuation allowance increased by $17,318, $8,836 and $13,218 in 2013, 2012, and 2011, respectively.
	At December 31, 2013, the Company had net federal operating loss carryforwards of approximately $329,400, which expire from 2018 to 2033 if not utilized.  The Company had state operating loss carryforwards of approximately $310,451, which expire from 2014 to 2033 if not utilized.  The Company also had research and development credits at December 31, 2013 of approximately $11,934, which expire from 2020 to 2033 if not utilized.
	Both of the net federal and state operating loss carryforwards include approximately $2,301 of deductions related to the exercise of stock options.  This amount represents an excess tax benefit and has not been included in the gross deferred income tax asset reflected for net federal and state operating loss carryforwards.  If utilized, the benefits from these deductions will be recorded as an adjustment to additional paid in capital.
	The Company will recognize the impact of a tax position in the financial statements if that position is more likely than not of being sustained on audit based on the technical merits of the position.  As of December 31, 2013, the Company had no unrecognized tax benefits.  Utilization of the Company’s net operating loss carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions.  The annual limitations may result in the expiration of net operating loss carryforwards before utilization.  The Company completed a study of its net operating losses through December 31, 2013 to determine whether such amounts are likely to be limited by Section 382.  As a result of this study, the Company does not currently believe any Section 382 limitation exists through December 31, 2013.  However, any future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.  The Company has not yet conducted an in depth study of its research and development credits, although the Company periodically reviews assumptions in its calculations to reflect its best estimate of expected credit.  The Company reduced the cumulative eligible credit by $1,122 as a result of its review during the year ended December 31, 2012.  An in depth study may result in an increase or decrease to the Company’s research and development credits and until such study is conducted of the Company’s research and development credits, no amounts are being presented as an uncertain tax position.  The Company’s net deferred income tax assets have been fully offset by a valuation allowance.  Therefore, future changes to the Company’s unrecognized tax benefits would be offset by an adjustment to the valuation allowance and there would be no impact on the Company’s balance sheet, statement of operations, or cash flows.  The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months.
	The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and the appropriate state income taxing authorities for all years due to the net loss carryforwards from those years.  The Company is currently not under examination by the Internal Revenue Service or any other taxing authorities.  The Company has not recorded any interest and penalties on any unrecognized tax benefits since its inception.
	The Company has recognized the tax effect of discontinued operations in the statements of operations for the years ended December 31, 2012 and 2011 in accordance with the intra-period accounting rules.  An offsetting tax benefit is recorded in continuing operations in each year in which tax expense was recognized for discontinued operations.

Directors_Deferred_Compensatio

Directors' Deferred Compensation Plan	12 Months Ended
	Dec. 31, 2013
Directors' Deferred Compensation Plan	'
Directors' Deferred Compensation Plan	'
	10.  Directors’ Deferred Compensation Plan
	Non-employee directors may defer all or a portion of their fees under the Company’s Directors’ Deferred Compensation Plan until termination of their status as directors.  Deferrals can be made into a cash account, a stock account, or a combination of both.  Stock accounts will be paid out in the form of Company common stock, except that any fractional shares will be paid out in cash valued at the then current market price of the Company’s common stock.  Cash accounts and stock accounts under the Directors’ Deferred Compensation Plan are credited with interest or the value of any cash and stock dividends, respectively.  Non-employee directors are fully vested in any amounts that they elect to defer under the Directors’ Deferred Compensation Plan.
	For the years ended December 31, 2013, 2012 and 2011, the Company incurred non-employee director fee expense of $259, $237 and $260, respectively, of which $135, $169 and $178 was deferred into stock accounts and will be paid in common stock following separation from service as a director.  At December 31, 2013, 169,384 shares of the Company’s common stock had been credited to individual director stock accounts under the Directors’ Deferred Compensation Plan, and no amounts had been credited to individual director cash accounts under the Directors’ Deferred Compensation Plan.

401k_Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2013
401(k) Plan	'
401(k) Plan	'
	11.       401(k) Plan
	The Company sponsors a 401(k) retirement savings plan that is available to all eligible employees. The plan is intended to qualify under Section 401(k) of the Internal Revenue Code of 1986, as amended. The plan provides that each participant may contribute up to a statutory limit of their pre-tax compensation which was $17.5 for employees under age 50 and $23 for employees 50 and older in calendar year 2013.  Employee contributions are held in the employees’ name and invested by the plan’s trustee. The plan also permits the Company to make matching contributions, subject to established limits.  The Company elected to match a portion of employee’s contributions to the plan in the amount of $338, $363 and $388 in 2013, 2012 and 2011, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	12.  Commitments and Contingencies
	Operating Lease Commitments
	The Company previously leased laboratory facilities and office space pursuant to a sublease, which had been accounted for as an operating lease.  Subsequent to the reduction in force implemented in October 2013, this lease was cancelled effective December 31, 2013.  See Note 13, Restructuring, for further discussion.  The Company subleases office space under a sublease that is accounted for as an operating lease.  This sublease has escalating rent payments and expires on April 30, 2015.  Total rent expense under the operating leases was approximately $674, $963 and $933 for the years ended December 31, 2013, 2012 and 2011, respectively.
	As of December 31, 2013, annual minimum payments under operating lease arrangements were as follows:
	2014	$	553
	2015	185
	Total	$	738

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2013
Restructuring	'
Restructuring	'
	13.       Restructuring
	In October 2013, the Company implemented a reduction in its workforce following the announced results from its two Phase 3 clinical trials evaluating enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced NSCLC.  The reduction in force was effective immediately and represented approximately 60% of the Company’s total workforce.
	As a result of the workforce reduction, the Company incurred severance related cash expenses of $1,306, of which $351 was included in general and administrative expenses and $955 was included in research and development expenses for the year ended December 31, 2013.  All of these expenses have been paid as of December 31, 2013.  Additionally, the Company recognized a net benefit of approximately $370 resulting from the reversal of share-based compensation expense related to the modification of certain stock option provisions for the severed employees.  Of this amount, $81 was included as a benefit to general and administrative expenses and $289 was included as a benefit to research and development expenses for the year ended December 31, 2013.
	As a result of the October 2013 reduction in its workforce, the Company is no longer conducting drug discovery activities.  During the fourth quarter of 2013, the Company cancelled its sublease for the laboratory facilities and office space utilized for drug discovery.  Additionally, the Company sold its related property and equipment for a gain of $1,366, which was included in other income (expense), net for the year ended December 31, 2013.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2013
Discontinued Operations	'
Discontinued Operations	'
	14.       Discontinued Operations
	On September 28, 2012, the Company entered into the FARESTON® Purchase Agreement with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights to FARESTON® and certain assets related thereto.  Effective September 30, 2012, the Company completed the sale of FARESTON® pursuant to the FARESTON® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory.  The Company recognized a gain of $18,831 on the sale of FARESTON® for the year ended December 31, 2012. The gain represents the gross proceeds received from the sale reduced by a contract termination fee of $1,000 due to Orion (as discussed further in Note 7, Collaboration and License Agreements), a financial advisory fee related to the transaction of $1,712, and other transaction expenses of approximately $128.
	The Company has accounted for FARESTON® as a discontinued operation.  The FARESTON® operating income for the years ended December 31, 2012 and 2011, along with the gain recognized on the sale of FARESTON® for the year ended December 31, 2012, has been reported in “net income from discontinued operations” in the statements of operations.
	FARESTON® operating income for each period presented was as follows:
		Years Ended December
		2012			2011
	Product sales, net	$	5,284		$	6,673
	Cost of product sales	(784		)	(1,055		)
	Operating expenses	(655		)	(3,411		)
	FARESTON® operating income	$	3,845		$	2,207
	Under the FARESTON® Purchase Agreement, the Company remains liable for future product returns relating to sales of FARESTON® made by the Company prior to September 30, 2012.  At December 31, 2013, liabilities related to FARESTON® discontinued operations were $918 and consisted of the Company’s accrual for product returns.  At December 31, 2012, total assets related to FARESTON® discontinued operations were $14 and consisted of accounts receivable, prepaid expenses and other assets.  At December 31, 2012, the total liabilities related to FARESTON® discontinued operations were $1,398 and consisted of accounts payable and other liabilities and the accrual for product returns of $1,189.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited)	'
Quarterly Financial Data (Unaudited)	'
	15.  Quarterly Financial Data (Unaudited)
	The following is a summary of the quarterly results of operations for the years ended December 31, 2013 and 2012:
		2013 Quarters Ended
		March 31			June 30			September 30			December 31
	Expenses:
	Research and development expenses	$	9,614		$	10,139		$	6,477		$	6,088
	General and administrative expenses	3,023			2,684			2,483			3,091
	Total expenses	12,637			12,823			8,960			9,179
	Loss from operations	(12,637		)	(12,823		)	(8,960		)	(9,179		)
	Other income, net	55			21			23			1,389
	Net loss	$	(12,582	)	$	(12,802	)	$	(8,937	)	$	(7,790	)
	Net loss per share — basic and diluted	$	(0.20	)	$	(0.20	)	$	(0.14	)	$	(0.12	)
	Weighted average shares outstanding:
	Basic and diluted	62,864,140			62,994,771			63,179,394			63,185,389
		2012 Quarters Ended
		March 31			June 30			September 30			December 31
	Expenses:
	Research and development expenses	$	9,835		$	9,237		$	9,764		$	10,051
	General and administrative expenses	2,588			2,400			2,999			2,858
	Total expenses	12,423			11,637			12,763			12,909
	Loss from operations	(12,423		)	(11,637		)	(12,763		)	(12,909		)
	Other income (expense), net	8			53			(47		)	(33		)
	Loss from operations before income taxes	(12,415		)	(11,584		)	(12,810		)	(12,942		)
	Income tax benefit	381			355			5,812			2,273
	Net loss from continuing operations	(12,034		)	(11,229		)	(6,998		)	(10,669		)
	Income (loss) from discontinued operations before income taxes	1,335			1,203			20,214			(76		)
	Income tax (expense) benefit	(381		)	(355		)	(8,115		)	30
	Net income (loss) from discontinued operations	954			848			12,099			(46		)
	Net (loss) income	$	(11,080	)	$	(10,381	)	$	5,101		$	(10,715	)
	Net (loss) income per share — basic and diluted:
	Net loss from continuing operations	$	(0.19	)	$	(0.18	)	$	(0.11	)	$	(0.17	)
	Net income from discontinued operations	0.01			0.01			0.19			—
	Net (loss) income per share	$	(0.18	)	$	(0.17	)	$	0.08		$	(0.17	)
	Weighted average shares outstanding:
	Basic and diluted	62,798,008			62,805,662			62,815,549			62,817,495

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).  Additionally, GTx operates in one business segment.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers highly liquid investments with initial maturities of three months or less to be cash equivalents.
Short-term Investments	'
	Short-term Investments
	At December 31, 2013 and 2012, short-term investments consisted of Federal Deposit Insurance Corporation (“FDIC”) insured certificates of deposit with original maturities of greater than three months and less than one year.
Property and Equipment	'
	Property and Equipment
	Property and equipment is stated at cost. Amortization of leasehold improvements is recognized over the shorter of the estimated useful life of the leasehold improvement or the lease term.  Depreciation is computed using the straight-line method over the estimated useful lives as follows:
	Laboratory and office equipment	3 to 5 years
	Leasehold improvements	3 to 7 years
	Furniture and fixtures	5 years
	Computer equipment and software	3 years
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments, which include cash, cash equivalents, short-term investments, and accounts payable approximate their fair values.  As the Company has the positive intent and ability to hold the certificates of deposit classified as short-term investments until maturity, these investments have been classified as held to maturity investments and are stated at cost, which approximates fair value.  The Company considers these to be Level 2 investments as the fair values of these investments are determined using third-party pricing sources, which generally utilize observable inputs, such as interest rates and maturities of similar assets.
Concentration of Risk	'
	Concentration of Risk
	Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term investments.  The Company has established guidelines relating to diversification and maturities of its cash equivalents and short-term investments which are designed to manage risk.  The Company’s cash and cash equivalents consist of bank deposits, certificates of deposit, and money market mutual funds.  Bank deposits may at times be in excess of FDIC insurance limits.  The Company’s short-term investments consist of FDIC insured certificates of deposit with original maturities of greater than three months and less than one year.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development expenses include, but are not limited to, the Company’s expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees.  The Company expenses these costs in the period in which they are incurred. The Company estimates its liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon the Company’s estimate of services received and degree of completion of the services in accordance with the specific third party contract.  As a result of the October 2013 reduction in its workforce, the Company is no longer conducting drug discovery activities and is focusing its research and development activities on the ongoing clinical development of the Company’s current product candidates.  See Note 13, Restructuring, for further discussion.
Patent Costs	'
	Patent Costs
	The Company expenses patent costs, including legal expenses, in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the Company’s statements of operations.
Income Taxes	'
	Income Taxes
	The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Accordingly, at December 31, 2013 and December 31, 2012, net of the valuation allowance, the net deferred tax assets were reduced to zero.  See Note 9, Income Taxes, for further discussion.
	The Company has recognized the tax effect of discontinued operations in the statements of operations in accordance with the intra-period accounting rules.  An offsetting tax benefit was recorded in continuing operations in each year in which tax expense was recognized for discontinued operations.
Share-Based Compensation	'
	Share-Based Compensation
	The Company has stock option and equity incentive plans that provide for the purchase or acquisition of the Company’s common stock by certain of the Company’s employees and non-employee directors.  The Company recognizes compensation expense for its share-based payments based on the fair value of the awards over the period during which an employee or non-employee director is required to provide service in exchange for the award.  See Note 3, Share-Based Compensation, for further discussion.
Other Income (Expense), Net	'
	Other Income (Expense), Net
	Other income (expense), net consists of foreign currency transaction gains and losses, interest earned on the Company’s cash, cash equivalents and short-term investments, interest expense, and other non-operating income or expense.  Additionally, other income (expense), net for the year ended December 31, 2013 included a gain of $1,366 from the sale of research and development property and equipment sold subsequent to the workforce reduction that occurred in October 2013.  See Note 4, Property and Equipment, Net, and Note 13, Restructuring, for further discussion.
Basic and Diluted Net Loss Per Share	'
	Basic and Diluted Net Loss Per Share
	Basic and diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of common shares outstanding during the period.  Diluted net loss per share gives effect to the dilutive potential of common stock consisting of stock options and unvested restricted stock units (“RSUs”).
	Weighted average potential shares of common stock of 6,773,394, 5,574,915, and 5,327,752 were excluded from the calculation of diluted net loss per share for the years ended December 31, 2013, 2012 and 2011, respectively, as inclusion of the potential shares would have had an anti-dilutive effect on the net loss per share for the periods.  At December 31, 2013, the Company had outstanding 63,185,389 shares of common stock.
Comprehensive Loss	'
	Comprehensive Loss
	For all periods presented, there were no differences between net loss and comprehensive loss.
Discontinued Operations	'
	Discontinued Operations
	Effective September 30, 2012, the Company entered into an asset purchase agreement (the “FARESTON® Purchase Agreement”) with Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights and certain assets related to FARESTON®.  The Company has accounted for FARESTON® as a discontinued operation.  As a result, revenue, cost of goods sold, and operating expenses related to FARESTON® were excluded from the respective captions in the statement of operations and were included in discontinued operations for the years ended December 31, 2012 and 2011.  See Note 14, Discontinued Operations, for further discussion.
FARESTON Revenue Recognition	'
	FARESTON® Revenue Recognition
	Revenue from product sales of FARESTON®, which is included in income from discontinued operations before income taxes for the years ended December 31, 2012 and 2011, was recognized less deductions for estimated sales discounts and sales returns.  Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured.  The Company accounted for rebates to certain governmental agencies as a reduction of product sales.  The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date.  Although the Company sold its rights and certain assets related to FARESTON® effective September 30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON® made by the Company prior to September 30, 2012.  Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date.  At December 31, 2013 and December 31, 2012, the Company’s accrual for product returns, was $918 and $1,189, respectively.   Of these amounts, $332 and $370 have been included in “Other long-term liabilities” in the balance sheet at December 31, 2013 and December 31, 2012, respectively, and represents the portion of the Company’s product returns accrual estimated to be payable after one year.  See Note 14, Discontinued Operations, for further discussion.
Collaboration Revenue Recognition	'
	Collaboration Revenue Recognition
	Collaboration revenue for the year ended December 31, 2011 consisted of non-refundable upfront payments and license fees associated with the Company’s former collaboration and license agreement with Ipsen Biopharm Limited.  Revenues from the prior collaboration and license agreement were recognized based on the performance requirements of the agreement.  The Company analyzed the agreement, which included multiple element arrangements, to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting.  See Note 7, Collaboration and License Agreements, for further discussion.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets.  An impairment loss is recognized when estimated future cash flows are less than the carrying amount.  The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time.  See Note 8, Intangible Assets, Net for further discussion.
Subsequent Events	'
	Subsequent Events
	The Company has evaluated all events or transactions that occurred after December 31, 2013 up through the date the financial statements were issued.  Other than as set forth below, there were no material recognizable or nonrecognizable subsequent events during the period evaluated.
	On March 6, 2014, the Company completed a private placement of units consisting of an aggregate of 11,976,048 shares of common stock and warrants to purchase an aggregate of 10,179,642 shares of our common stock per unit for gross proceeds of $21,272.  The warrants, which have a one year term, have a per share exercise price of $1.67 that is payable only in cash.  Pursuant to the terms of a registration rights agreement dated March 6, 2014 that the Company entered into with the investors, the Company agreed to file a registration statement under the Securities Act registering the resale of all 22,155,690 shares held by or issuable to the investors.  No underwriting discounts or commissions or similar fees were payable in connection with the issuance.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies	'
Schedule of estimated useful lives of property and equipment	'
	Laboratory and office equipment	3 to 5 years
	Leasehold improvements	3 to 7 years
	Furniture and fixtures	5 years
	Computer equipment and software	3 years

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Share-Based Compensation	'
Summary of share-based compensation expense	'
		Years Ended December 31,
		2013			2012			2011
	Research and development expenses	$	1,875		$	1,046		$	1,972
	General and administrative expenses	1,993			1,771			2,432
	Total share-based compensation	$	3,868		$	2,817		$	4,404
Schedule of assumptions used to estimate fair value of options	'
		Years Ended December 31,
		2013		2012		2011
	Expected price volatility	82.9	%	69.6	%	64.9	%
	Risk-free interest rate	1.27	%	1.22	%	2.54	%
	Weighted average expected life in years	5.9 years		6.5 years		6.5 years
	Dividend yield	0	%	0	%	0	%
Summary of stock option transactions	'
		Number of		Weighted
		Shares		Average
				Exercise Price
				Per Share
	Options outstanding at January 1, 2011	4,430,495		10.91
	Options granted	1,395,000		2.82
	Options forfeited or expired	(866,930	)	8.23
	Options exercised	(13,000	)	4.2
	Options outstanding at December 31, 2011	4,945,565		9.12
	Options granted	1,141,250		3.35
	Options forfeited or expired	(675,755	)	8.82
	Options exercised	(28,201	)	3.05
	Options outstanding at December 31, 2012	5,382,859		7.96
	Options granted	2,784,200		3.12
	Options forfeited or expired	(1,400,419	)	5.86
	Options exercised	(321,298	)	3.81
	Options outstanding at December 31, 2013	6,445,342		6.58
	Options vested and expected to vest at December 31, 2013	6,378,284		6.61
Schedule of stock option activity by exercise price range	'
	Options Outstanding								Options Exercisable
	Exercise Price	Number		Weighted		Weighted			Number	Weighted
		Outstanding		Average		Average			Exercisable	Average
				Remaining		Exercise Price				Exercise
				Contractual						Price
				Life (years)
	$1.51 - $3.36	2,662,100		7.79		$	2.49		642,501	$	2.96
	$3.44 - $9.71	2,150,947		5.77		4.88			1,023,482	5.58
	$9.80 - $20.40	1,632,295		2.63		15.48			1,515,137	15.43
		6,445,342		5.81		6.58			3,181,120	9.74
Summary of the Company's restricted stock units	'
		Number of		Weighted
		Shares		Average Grant
				Date Fair Value
				Per Share
	Unvested RSUs at January 1, 2013	—		—
	RSUs granted	1,325,000		1.87
	RSUs vested	—		—
	RSUs forfeited	(100,000	)	1.88
	Unvested RSUs at December 31, 2013 2013	1,225,000		1.87

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment, Net	'
Schedule of property and equipment, net	'
		December 31,
		2013			2012
	Computer equipment and software	$	2,130		$	4,177
	Furniture and fixtures	1,032			2,706
	Leasehold improvements	355			1,361
	Office and laboratory equipment	261			1,024
		3,778			9,268
	Less: accumulated depreciation	(3,666		)	(8,761		)
		$	112		$	507

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities	'
Schedule of accrued expenses and other current liabilities	'
		December 31,
		2013		2012
	Employee compensation	$	1,354	$	294
	Clinical trials	1,127		5,621
	Product returns	586		819
	Selling, general and administrative	497		737
	Research and development	39		46
	Net deferred income tax liabilities	156		271
		$	3,759	$	7,788

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Schedule of principal components of the Company's net deferred income tax assets and liabilities	'
		December 31,
		2013			2012
	Deferred income tax assets, net:
	Net federal and state operating loss carryforwards	$	127,819		$	112,233
	Research and development credits	11,934			9,799
	Share-based compensation	8,670			8,852
	Depreciation and amortization	170			331
	Other, net	268			328
	Total deferred tax assets, net	148,861			131,543
	Valuation allowance	(148,861		)	(131,543		)
	Net deferred tax assets and liabilities	$	—		$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
Schedule of annual minimum payments under operating lease arrangements	'
	2014	$	553
	2015	185
	Total	$	738

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Discontinued Operations	'
Operating income related to discontinued operations	'
		Years Ended December
		2012			2011
	Product sales, net	$	5,284		$	6,673
	Cost of product sales	(784		)	(1,055		)
	Operating expenses	(655		)	(3,411		)
	FARESTON® operating income	$	3,845		$	2,207

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited)	'
Summary of the quarterly results of operations	'
		2013 Quarters Ended
		March 31			June 30			September 30			December 31
	Expenses:
	Research and development expenses	$	9,614		$	10,139		$	6,477		$	6,088
	General and administrative expenses	3,023			2,684			2,483			3,091
	Total expenses	12,637			12,823			8,960			9,179
	Loss from operations	(12,637		)	(12,823		)	(8,960		)	(9,179		)
	Other income, net	55			21			23			1,389
	Net loss	$	(12,582	)	$	(12,802	)	$	(8,937	)	$	(7,790	)
	Net loss per share — basic and diluted	$	(0.20	)	$	(0.20	)	$	(0.14	)	$	(0.12	)
	Weighted average shares outstanding:
	Basic and diluted	62,864,140			62,994,771			63,179,394			63,185,389
		2012 Quarters Ended
		March 31			June 30			September 30			December 31
	Expenses:
	Research and development expenses	$	9,835		$	9,237		$	9,764		$	10,051
	General and administrative expenses	2,588			2,400			2,999			2,858
	Total expenses	12,423			11,637			12,763			12,909
	Loss from operations	(12,423		)	(11,637		)	(12,763		)	(12,909		)
	Other income (expense), net	8			53			(47		)	(33		)
	Loss from operations before income taxes	(12,415		)	(11,584		)	(12,810		)	(12,942		)
	Income tax benefit	381			355			5,812			2,273
	Net loss from continuing operations	(12,034		)	(11,229		)	(6,998		)	(10,669		)
	Income (loss) from discontinued operations before income taxes	1,335			1,203			20,214			(76		)
	Income tax (expense) benefit	(381		)	(355		)	(8,115		)	30
	Net income (loss) from discontinued operations	954			848			12,099			(46		)
	Net (loss) income	$	(11,080	)	$	(10,381	)	$	5,101		$	(10,715	)
	Net (loss) income per share — basic and diluted:
	Net loss from continuing operations	$	(0.19	)	$	(0.18	)	$	(0.11	)	$	(0.17	)
	Net income from discontinued operations	0.01			0.01			0.19			—
	Net (loss) income per share	$	(0.18	)	$	(0.17	)	$	0.08		$	(0.17	)
	Weighted average shares outstanding:
	Basic and diluted	62,798,008			62,805,662			62,815,549			62,817,495

Significant_Accounting_Policie3

Significant Accounting Policies (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	item
Significant Accounting Policies	'	'	'
Number of business segments	1	'	'
Income Taxes	'	'	'
Net deferred tax assets	$0	$0	'
Other Income (Expense), Net	'	'	'
Gain on sale of property and equipment	1,366	'	'
Basic and Diluted Net Loss Per Share	'	'	'
Weighted average potential shares of common stock excluded from calculation of diluted net loss per share	6,773,394	5,574,915	5,327,752
Common stock, shares outstanding	63,185,389	62,818,424	'
FARESTON Revenue Recognition	'	'	'
Accrual for product returns	918	1,189	'
Accrual for product returns included in other long term liabilities	$332	$370	'
Laboratory and office equipment | Minimum	'	'	'
Property and equipment	'	'	'
Estimated useful lives	'3 years	'	'
Laboratory and office equipment | Maximum	'	'	'
Property and equipment	'	'	'
Estimated useful lives	'5 years	'	'
Leasehold improvements | Minimum	'	'	'
Property and equipment	'	'	'
Estimated useful lives	'3 years	'	'
Leasehold improvements | Maximum	'	'	'
Property and equipment	'	'	'
Estimated useful lives	'7 years	'	'
Furniture and fixtures	'	'	'
Property and equipment	'	'	'
Estimated useful lives	'5 years	'	'
Computer equipment and software	'	'	'
Property and equipment	'	'	'
Estimated useful lives	'3 years	'	'

Significant_Accounting_Policie4

Significant Accounting Policies (Details 2) (USD $)	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 28, 2011	Nov. 01, 2010	Mar. 06, 2014
			Subsequent event
			Private placement
Subsequent event	'	'	'
Shares issued	10,000,000	14,285,715	11,976,048
Warrants issued to purchase shares under private placement	'	'	10,179,642
Gross proceeds from issuance under private placement	'	'	$21,272
Warrant term	'	'	'1 year
Exercise price (in dollars per share)	'	'	$1.67
Number of shares to be registered by a registration statement under Securities Act	'	'	22,155,690

ShareBased_Compensation_Detail

Share-Based Compensation (Details)	Dec. 31, 2013	2-May-13	2-May-13	2-May-13	2-May-13	2-May-13	2-May-13	2-May-13	2-May-13
		2013 EIP	2013 EIP	2013 EIP	2013 NEDEIP	2013 NEDEIP	2013 NEDEIP	Prior Plans	2004 NEDSOP
			Minimum	Maximum		Minimum	Maximum
Share-based compensation	'	'	'	'	'	'	'	'	'
Number of shares initially available for issuance	'	4,208,157	'	'	404,000	'	'	'	'
Additional number of shares available for issuance subject to the expiration or forfeiture of awards granted under prior share-based compensation plans	'	'	'	6,093,559	'	'	449,667	'	'
Period for which common stock available for issuance under the plan will automatically increase on January 1st of each year	'	'10 years	'	'	'10 years	'	'	'	'
Annual increase in common stock available for issuance under the plan as a percentage of the total number of shares of the Company's common stock outstanding on December 31 of the preceding calendar year	'	'	'	4.00%	'	'	1.00%	'	'
Annual increase in common stock available for issuance under the plan each year (in shares)	'	'	'	'	'	'	500,000	'	'
Increase in common stock available for issuance under the plan as may be approved by the Company's Board of Directors	'	'	0	'	'	0	'	'	'
Awards available for grant	3,239,443	'	'	'	'	'	'	0	0

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2011
				item
Share-based compensation expense	'	'	'	'
Term of options from the grant date	'10 years	'	'	'
Total share-based compensation	$3,868	$2,817	$4,404	'
Share-based compensation expense related to deferred compensation arrangements for non-employee directors	135	169	178	'
Number of terminated non-executive officers	'	'	'	3
Reversal of previously recognized share-based compensation expense for non-vested stock options canceled in conjunction with the total workforce reduction	'	'	704	'
Share-based compensation expense related to discontinued operations	0	0	'	'
One-time share based compensation benefit related to modification of stock option provisions	'	'	'	'
Share-based compensation expense	'	'	'	'
Expense (benefit) related to workforce reduction	-370	'	'	'
Research and development expenses	'	'	'	'
Share-based compensation expense	'	'	'	'
Total share-based compensation	1,875	1,046	1,972	'
Reversal of previously recognized share-based compensation expense for non-vested stock options canceled in conjunction with the total workforce reduction	'	'	58	'
Research and development expenses | One-time share based compensation benefit related to modification of stock option provisions	'	'	'	'
Share-based compensation expense	'	'	'	'
Expense (benefit) related to workforce reduction	-289	'	'	'
General and administrative expenses	'	'	'	'
Share-based compensation expense	'	'	'	'
Total share-based compensation	1,993	1,771	2,432	'
One-time share-based compensation charge related to the modification of options of terminated non-executive officers	'	'	481	'
Reversal of previously recognized share-based compensation expense for non-vested stock options canceled in conjunction with the total workforce reduction	'	'	646	'
Share-based compensation expense related to discontinued operations	'	'	137	'
General and administrative expenses | One-time share based compensation benefit related to modification of stock option provisions	'	'	'	'
Share-based compensation expense	'	'	'	'
Expense (benefit) related to workforce reduction	-81	'	'	'
Non-employee Directors	'	'	'	'
Share-based compensation expense	'	'	'	'
Option vesting period	'3 years	'	'	'
Share-based compensation expense related to deferred compensation arrangements for non-employee directors	135	169	178	'
Non-employee Directors | General and administrative expenses	'	'	'	'
Share-based compensation expense	'	'	'	'
Share-based compensation expense related to deferred compensation arrangements for non-employee directors	$135	$169	$178	'
Employees	'	'	'	'
Share-based compensation expense	'	'	'	'
Period available to exercise all vested options after end of employment relationship	'3 months	'	'	'
Option vesting period after employee's termination of service before modification	'90 days	'	'	'
Modified option vesting period after employee's termination of service	'6 months	'	'	'
Employees | Maximum	'	'	'	'
Share-based compensation expense	'	'	'	'
Option vesting period	'5 years	'	'	'

ShareBased_Compensation_Detail2

Share-Based Compensation (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-Based Compensation	'	'	'
Weighted average grant date fair value (in dollars per share)	$2.13	$2.14	$1.75
Fair value of options granted	'	'	'
Expected price volatility (as a percent)	82.90%	69.60%	64.90%
Risk-free interest rate (as a percent)	1.27%	1.22%	2.54%
Weighted average expected life in years	'5 years 10 months 24 days	'6 years 6 months	'6 years 6 months
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Option term	'10 years	'	'
Number of Shares	'	'	'
Options outstanding at the beginning of the period (in shares)	5,382,859	4,945,565	4,430,495
Options granted (in shares)	2,784,200	1,141,250	1,395,000
Options forfeited or expired (in shares)	-1,400,419	-675,755	-866,930
Options exercised (in shares)	-321,298	-28,201	-13,000
Options outstanding at the end of the period (in shares)	6,445,342	5,382,859	4,945,565
Options vested and expected to vest at the end of the period (in shares)	6,378,284	'	'
Weighted Average Exercise Price Per Share	'	'	'
Options outstanding at the beginning of the period (in dollars per share)	$7.96	$9.12	$10.91
Options granted (in dollars per share)	$3.12	$3.35	$2.82
Options forfeited or expired (in dollars per share)	$5.86	$8.82	$8.23
Options exercised (in dollars per share)	$3.81	$3.05	$4.20
Options outstanding at the end of the period (in dollars per share)	$6.58	$7.96	$9.12
Options vested and expected to vest at the end of the period (in dollars per share)	$6.61	'	'

ShareBased_Compensation_Detail3

Share-Based Compensation (Details 4) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 02, 2014
Information about stock options outstanding	'	'	'	'
Options Outstanding, Number Outstanding (in shares)	6,445,342	'	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'5 years 9 months 22 days	'	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$6.58	'	'	'
Options Exercisable, Number Exercisable (in shares)	3,181,120	'	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$9.74	'	'	'
Additional information	'	'	'	'
Options exercisable, weighted average remaining contractual term	'2 years 11 months 1 day	'	'	'
Options exercisable, aggregate intrinsic value (in dollars)	$0	'	'	'
Vested and expected to vest options, weighted average remaining contractual term	'5 years 9 months 11 days	'	'	'
Number of Shares Options exercised	321,298	28,201	13,000	'
Intrinsic value of options exercised (in dollars)	688	36	15	'
Compensation cost related to non-vested options not yet recognized	4,390	'	'	'
Weighted average expense recognition period related to non-vested options not yet recognized	'1 year 11 months 19 days	'	'	'
Shares available for future issuance under the Company's stock option and equity incentive plans	3,239,443	'	'	'
Increase to shares available for future issuance in accordance with annual automatic increase provisions	'	'	'	3,027,416
Maximum	'	'	'	'
Additional information	'	'	'	'
Aggregate intrinsic value of all outstanding options (in dollars)	1	'	'	'
Vested and expected to vest options, intrinsic value (in dollars)	$1	'	'	'
$1.51 - $3.36	'	'	'	'
Information about stock options outstanding	'	'	'	'
Low end of range of exercise prices (in dollars per share)	$1.51	'	'	'
High end of range of exercise prices (in dollars per share)	$3.36	'	'	'
Options Outstanding, Number Outstanding (in shares)	2,662,100	'	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'7 years 9 months 14 days	'	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$2.49	'	'	'
Options Exercisable, Number Exercisable (in shares)	642,501	'	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$2.96	'	'	'
$3.44 - $9.71	'	'	'	'
Information about stock options outstanding	'	'	'	'
Low end of range of exercise prices (in dollars per share)	$3.44	'	'	'
High end of range of exercise prices (in dollars per share)	$9.71	'	'	'
Options Outstanding, Number Outstanding (in shares)	2,150,947	'	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'5 years 9 months 7 days	'	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$4.88	'	'	'
Options Exercisable, Number Exercisable (in shares)	1,023,482	'	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$5.58	'	'	'
$9.80 - $20.40	'	'	'	'
Information about stock options outstanding	'	'	'	'
Low end of range of exercise prices (in dollars per share)	$9.80	'	'	'
High end of range of exercise prices (in dollars per share)	$20.40	'	'	'
Options Outstanding, Number Outstanding (in shares)	1,632,295	'	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'2 years 7 months 17 days	'	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$15.48	'	'	'
Options Exercisable, Number Exercisable (in shares)	1,515,137	'	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$15.43	'	'	'

ShareBased_Compensation_Detail4

Share-Based Compensation (Details 5) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013
Share-based compensation additional disclosure	'
Weighted average expense recognition period related to restricted stock units not yet recognized	'1 year 11 months 19 days
Restricted stock units	'
Number of Shares	'
Restricted stock units granted (in shares)	1,325,000
Restricted stock units forfeited (in shares)	-100,000
Unvested restricted stock units outstanding at the end of the period (in shares)	1,225,000
Restricted stock units granted (in dollars per share)	1.87
Restricted stock units forfeited (in dollars per share)	1.88
Unvested restricted stock units outstanding at the end of the period (in dollars per share)	1.87
Share-based compensation additional disclosure	'
Compensation cost related to non-vested restricted stock units not yet recognized	1,443
Weighted average expense recognition period related to restricted stock units not yet recognized	'5 months

Property_and_Equipment_Net_Det

Property and Equipment, Net (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and equipment	'	'	'
Property and Equipment, gross	$3,778	$9,268	'
Less: accumulated depreciation	-3,666	-8,761	'
Property and Equipment, Net	112	507	'
Depreciation and amortization expense	369	730	998
Gain on sale of property and equipment	1,366	'	'
Research and development expenses	'	'	'
Property and equipment	'	'	'
Depreciation and amortization expense	169	290	425
Computer equipment and software	'	'	'
Property and equipment	'	'	'
Property and Equipment, gross	2,130	4,177	'
Furniture and fixtures	'	'	'
Property and equipment	'	'	'
Property and Equipment, gross	1,032	2,706	'
Leasehold improvements	'	'	'
Property and equipment	'	'	'
Property and Equipment, gross	355	1,361	'
Office and laboratory equipment	'	'	'
Property and equipment	'	'	'
Property and Equipment, gross	261	1,024	'
Property and equipment sold	$58	'	'

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities	'	'
Employee compensation	$1,354	$294
Clinical trials	1,127	5,621
Product returns	586	819
General and administrative	497	737
Research and development	39	46
Net deferred income tax liabilities	156	271
Accrued expenses and other current liabilities	$3,759	$7,788

Common_and_Preferred_Stock_Det

Common and Preferred Stock (Details) (USD $)	0 Months Ended		12 Months Ended				0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 28, 2011	Nov. 01, 2010	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	6-May-11	Jun. 28, 2011	Nov. 24, 2010	Nov. 01, 2010	Jun. 28, 2011	Nov. 01, 2010
							Underwriters	Underwriters	Underwriters	Underwriters	Underwriters
										Maximum	Maximum
Common and preferred stock	'	'	'	'	'	'	'	'	'	'	'
Common stock shares authorized prior to amendment	'	'	'	'	'	60,000,000	'	'	'	'	'
Common stock shares authorized	'	'	'	120,000,000	120,000,000	120,000,000	'	'	'	'	'
Par value per share (in dollars per share)	'	'	'	$0.00	$0.00	$0.00	'	'	'	'	'
Preferred stock shares authorized	'	'	'	5,000,000	'	'	'	'	'	'	'
Par value per share (in dollars per share)	'	'	'	$0.00	'	'	'	'	'	'	'
Shares issued	10,000,000	14,285,715	'	'	'	'	1,023,000	1,000,000	'	'	'
Share price (in dollars per share)	$4.75	$2.80	'	'	'	'	$4.75	$2.80	'	'	'
Net cash proceeds from public offering after deducting underwriting discounts and commissions and other offering expenses	$49,000	$37,700	$48,982	'	'	'	'	$2,600	'	'	'
Period of option granted to underwriter to purchase additional shares to cover over-allotments	'	'	'	'	'	'	'30 days	'	'30 days	'	'
Shares for which purchase options are granted to underwriter to cover over-allotments	'	'	'	'	'	'	'	'	'	1,500,000	2,142,857

Collaboration_and_License_Agre1

Collaboration and License Agreements (Details)	12 Months Ended	1 Months Ended		3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011	Oct. 31, 2012	Sep. 30, 2006	Mar. 31, 2011	Sep. 30, 2006
	USD ($)	Former Orion Corporation License and Supply Agreement	Former Ipsen Collaboration and License Agreement	Former Ipsen Collaboration and License Agreement	Former Ipsen Collaboration and License Agreement
		USD ($)	EUR (€)	USD ($)	USD ($)
Collaboration and license agreements disclosures	'	'	'	'	'
Contract termination fee	'	$1,000	'	'	'
License fee and expense reimbursement	'	'	23,000	'	'
Deferred revenue related to upfront license fee and expense reimbursement	'	'	'	'	29,330
Development period	'	'	'10 years	'	'
Collaboration revenue	$8,066	'	'	$8,066	'

Intangible_Assets_Net_Details

Intangible Assets, Net (Details) (USD $)	12 Months Ended		0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2011	Jan. 01, 2005	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2007
		Toremifene 80 mg	Former Orion Corporation License and Supply Agreement	SARM License Agreement	SARM License Agreement	SARM License Agreement
Intangible assets, net	'	'	'	'	'	'
License fee	'	'	$4,826	'	'	'
One-time up-front fee	'	'	'	'	'	290
Impairment charge	1,598	1,598	'	'	'	'
Intangible asset, net	'	'	'	$166	$181	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred income tax assets, net:	'	'	'
Net federal and state operating loss carryforwards	$127,819	$112,233	'
Research and development credits	11,934	9,799	'
Share-based compensation	8,670	8,852	'
Depreciation and amortization	170	331	'
Other, net	268	328	'
Total deferred tax assets, net	148,861	131,543	'
Valuation allowance	-148,861	-131,543	'
Net deferred tax assets and liabilities	0	0	'
Valuation allowance disclosure	'	'	'
Increase in valuation allowance	17,318	8,836	13,218
Tax credits	'	'	'
Unrecognized tax benefits	0	'	'
Decrease in research and development credit	'	1,122	'
Federal	'	'	'
Operating loss carryforwards	'	'	'
Net operating loss carryforwards	329,400	'	'
State	'	'	'
Operating loss carryforwards	'	'	'
Net operating loss carryforwards	310,451	'	'
Federal and state	'	'	'
Operating loss carryforwards	'	'	'
Deductions related to the exercise of stock options	$2,301	'	'

Directors_Deferred_Compensatio1

Directors' Deferred Compensation Plan (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Directors' deferred compensation plan	'	'	'
Non-employee director fee expense which was deferred into stock accounts	$135	$169	$178
Non-employee directors	'	'	'
Directors' deferred compensation plan	'	'	'
Non-employee director fee expense	259	237	260
Non-employee director fee expense which was deferred into stock accounts	135	169	178
Shares of common stock credited to individual director stock accounts under the Directors' Deferred Compensation Plan	169,384	'	'
Amount credited to individual director cash accounts under the Directors' Deferred Compensation Plan	$0	'	'

401k_Plan_Details

401(k) Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	item
401(k) Plan	'	'	'
Maximum annual contribution per employee who is under the specified age in the current calendar year	$17,500	'	'
Age specified for current calendar year to determine employee's contribution	50	'	'
Maximum annual contribution per employee who is equal to specified age and older in the current calendar year	23,000	'	'
Company's matching contribution to the plan	$338,000	$363,000	$388,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies	'	'	'
Rent expense under operating leases	$674	$963	$933
Operating Lease Commitments	'	'	'
2014	553	'	'
2015	185	'	'
Total	$738	'	'

Restructuring_Details

Restructuring (Details) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Dec. 31, 2013
Restructuring	'	'
Reduction in workforce (as a percent)	60.00%	'
Gain on sale of property and equipment	'	$1,366
One-time compensation expense related to cash severance	'	'
Restructuring	'	'
Expense (benefit) related to workforce reduction	'	1,306
One-time compensation expense related to cash severance | General and administrative expenses	'	'
Restructuring	'	'
Expense (benefit) related to workforce reduction	'	351
One-time compensation expense related to cash severance | Research and development expenses	'	'
Restructuring	'	'
Expense (benefit) related to workforce reduction	'	955
One-time share based compensation benefit related to modification of stock option provisions	'	'
Restructuring	'	'
Expense (benefit) related to workforce reduction	'	-370
One-time share based compensation benefit related to modification of stock option provisions | General and administrative expenses	'	'
Restructuring	'	'
Expense (benefit) related to workforce reduction	'	-81
One-time share based compensation benefit related to modification of stock option provisions | Research and development expenses	'	'
Restructuring	'	'
Expense (benefit) related to workforce reduction	'	($289)

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	12 Months Ended	1 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Oct. 31, 2012	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2012
		Former Orion Corporation License and Supply Agreement	FARESTON	FARESTON	FARESTON
					Former Orion Corporation License and Supply Agreement
Discontinued Operations disclosures	'	'	'	'	'
Proceeds from the sale of rights and certain assets related to FARESTON	'	'	$21,671	'	'
Gain on sale of FARESTON	18,831	'	'	18,831	'
Contract termination fee	'	1,000	'	'	1,000
Financial advisory fee	'	'	'	1,712	'
Other transaction expenses	'	'	'	$128	'

Discontinued_Operations_Detail1

Discontinued Operations (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Operating income (loss) related to discontinued operations	'	'	'
Accrual for product returns	$1,189	'	$918
FARESTON	'	'	'
Operating income (loss) related to discontinued operations	'	'	'
Product sales, net	5,284	6,673	'
Cost of product sales	-784	-1,055	'
Operating expenses	-655	-3,411	'
FARESTON operating income	3,845	2,207	'
Liabilities related to discontinued operations	1,398	'	918
Accrual for product returns	1,189	'	'
Assets related to discontinued operations	$14	'	'

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Expenses:	'	'	'	'	'	'	'	'	'	'	'
Research and development expenses	$6,088	$6,477	$10,139	$9,614	$10,051	$9,764	$9,237	$9,835	$32,318	$38,887	$31,938
General and administrative expenses	3,091	2,483	2,684	3,023	2,858	2,999	2,400	2,588	11,281	10,845	12,027
Total expenses	9,179	8,960	12,823	12,637	12,909	12,763	11,637	12,423	43,599	49,732	43,965
Loss from operations	-9,179	-8,960	-12,823	-12,637	-12,909	-12,763	-11,637	-12,423	-43,599	-49,732	-35,899
Other income, net	1,389	23	21	55	-33	-47	53	8	1,488	-19	398
Loss from operations before income taxes	-7,790	-8,937	-12,802	-12,582	-12,942	-12,810	-11,584	-12,415	-42,111	-49,751	-35,501
Income tax benefit	'	'	'	'	2,273	5,812	355	381	'	8,821	886
Net loss from continuing operations	'	'	'	'	-10,669	-6,998	-11,229	-12,034	-42,111	-40,930	-34,615
Income (loss) from discontinued operations before income taxes	'	'	'	'	-76	20,214	1,203	1,335	'	22,676	2,207
Income tax (expense) benefit	'	'	'	'	30	-8,115	-355	-381	'	-8,821	-886
Net income from discontinued operations	'	'	'	'	-46	12,099	848	954	'	13,855	1,321
Net loss	'	'	'	'	($10,715)	$5,101	($10,381)	($11,080)	($42,111)	($27,075)	($33,294)
Net (loss) income per share - basic and diluted:	'	'	'	'	'	'	'	'	'	'	'
Net loss from continuing operations (in dollars per share)	'	'	'	'	($0.17)	($0.11)	($0.18)	($0.19)	($0.67)	($0.65)	($0.60)
Net income from discontinued operations (in dollars per share)	'	'	'	'	'	$0.19	$0.01	$0.01	'	$0.22	$0.02
Net loss per share (in dollars per share)	($0.12)	($0.14)	($0.20)	($0.20)	($0.17)	$0.08	($0.17)	($0.18)	($0.67)	($0.43)	($0.58)
Weighted average shares outstanding:	'	'	'	'	'	'	'	'	'	'	'
Basic and diluted (in shares)	63,185,389	63,179,394	62,994,771	62,864,140	62,817,495	62,815,549	62,805,662	62,798,008	63,057,142	62,809,219	57,359,466